Sectors & IndustriesHealthcareMedical Instruments & Supplies
Best Medical Stocks to Buy Now (2026)
Top medical stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best medical stocks to buy now. Learn More.

Industry: Medical Instruments & Sup...
A
Medical is Zen Rated A and is the 24th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
DD Score
Valuation Score
Financials Score
Forecast Score
Performance Score
Dividends Score
INFU
INFUSYSTEM HOLDINGS INC
38
14
86
11
40
–
ICUI
ICU MEDICAL INC
30
14
43
44
20
–
BLCO
BAUSCH & LOMB CORP
16
14
29
0
20
–
HAE
HAEMONETICS CORP
30
0
43
56
20
–
MMSI
MERIT MEDICAL SYSTEMS INC
53
57
71
22
60
–

Upgrade to Premium to View More

Use Due Diligence Score to quickly analyze stock fundamentals, even if you don't have a finance background. We run time-tested due diligence checks inspired by legendary investors like Warren Buffett, and score each company based on how many they pass/fail.

Already have access to Premium? Sign In

Medical Stocks FAQ

What are the best medical stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

1. Infusystem Holdings (NYSEMKT:INFU)


Infusystem Holdings (NYSEMKT:INFU) is the #1 top medical stock out of 51 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: A, Sentiment: A, Safety: C, Financials: A, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 38, which is 6 points higher than the medical industry average of 32.

INFU passed 12 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock return 51.51% over the past year, overperforming other medical stocks by 43 percentage points.

Infusystem Holdings has an average 1 year price target of $20.00, an upside of 42.25% from Infusystem Holdings's current stock price of $14.06.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Icu Medical (NASDAQ:ICUI)


Icu Medical (NASDAQ:ICUI) is the #2 top medical stock out of 51 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Icu Medical (NASDAQ:ICUI) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: C.

Icu Medical (NASDAQ:ICUI) has a Due Diligence Score of 30, which is -2 points lower than the medical industry average of 32. Although this number is below the industry average, our proven quant model rates ICUI as a "A".

ICUI passed 10 out of 33 due diligence checks and has average fundamentals. Icu Medical has seen its stock return 32.58% over the past year, overperforming other medical stocks by 24 percentage points.

Icu Medical has an average 1 year price target of $194.00, an upside of 10.38% from Icu Medical's current stock price of $175.76.

Icu Medical stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Icu Medical, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Bausch & Lomb (NYSE:BLCO)


Bausch & Lomb (NYSE:BLCO) is the #3 top medical stock out of 51 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bausch & Lomb (NYSE:BLCO) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: B, Financials: C, and AI: C.

Bausch & Lomb (NYSE:BLCO) has a Due Diligence Score of 16, which is -16 points lower than the medical industry average of 32. Although this number is below the industry average, our proven quant model rates BLCO as a "A".

BLCO passed 5 out of 33 due diligence checks and has weak fundamentals. Bausch & Lomb has seen its stock return 41.52% over the past year, overperforming other medical stocks by 33 percentage points.

Bausch & Lomb has an average 1 year price target of $22.22, an upside of 7.4% from Bausch & Lomb's current stock price of $20.69.

Bausch & Lomb stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Bausch & Lomb, 30% have issued a Strong Buy rating, 20% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the medical stocks with highest dividends?

Out of 11 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

1. Embecta (NASDAQ:EMBC)


Embecta (NASDAQ:EMBC) has an annual dividend yield of 5.17%, which is 4 percentage points higher than the medical industry average of 1.41%. Embecta's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Embecta's dividend has not shown consistent growth over the last 10 years.

Embecta's dividend payout ratio of 30.7% indicates that its high dividend yield is sustainable for the long-term.

2. Becton Dickinson & Co (NYSE:BDX)


Becton Dickinson & Co (NYSE:BDX) has an annual dividend yield of 1.97%, which is 1 percentage points higher than the medical industry average of 1.41%. Becton Dickinson & Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Becton Dickinson & Co's dividend has shown consistent growth over the last 10 years.

Becton Dickinson & Co's dividend payout ratio of 126.2% indicates that its dividend yield might not be sustainable for the long-term.

3. Utah Medical Products (NASDAQ:UTMD)


Utah Medical Products (NASDAQ:UTMD) has an annual dividend yield of 1.75%, which is the same as the medical industry average of 1.41%. Utah Medical Products's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Utah Medical Products's dividend has shown consistent growth over the last 10 years.

Utah Medical Products's dividend payout ratio of 37.1% indicates that its dividend yield is sustainable for the long-term.

Why are medical stocks down?

Medical stocks were down -2.08% in the last day, and down -2.64% over the last week.

We couldn't find a catalyst for why medical stocks are down.

What are the most undervalued medical stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

1. Embecta (NASDAQ:EMBC)


Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 38 points higher than the medical industry average of 19. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -56.22% in the past year. It has underperformed other stocks in the medical industry by -65 percentage points.

2. Envista Holdings (NYSE:NVST)


Envista Holdings (NYSE:NVST) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Envista Holdings has a valuation score of 43, which is 24 points higher than the medical industry average of 19. It passed 3 out of 7 valuation due diligence checks.

Envista Holdings's stock has gained 22.8% in the past year. It has overperformed other stocks in the medical industry by 15 percentage points.

3. Cooper Companies (NASDAQ:COO)


Cooper Companies (NASDAQ:COO) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Cooper Companies has a valuation score of 57, which is 38 points higher than the medical industry average of 19. It passed 4 out of 7 valuation due diligence checks.

Cooper Companies's stock has dropped -16.38% in the past year. It has underperformed other stocks in the medical industry by -25 percentage points.

Are medical stocks a good buy now?

40.54% of medical stocks rated by analysts are a strong buy right now. On average, analysts expect medical stocks to rise by 14.44% over the next year.

15.38% of medical stocks have a Zen Rating of A (Strong Buy), 23.08% of medical stocks are rated B (Buy), 51.28% are rated C (Hold), 10.26% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the medical instruments & supplies industry?

The average P/E ratio of the medical instruments & supplies industry is 23.99x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.